SMARCA2 and neoplasm: Thus, while several mechanisms have been identified that potentially contribute to the attenuated ability of BrM to induce anti-tumor responses (Figure 1), the evidence for differential expression of immune checkpoints in BrM and primary tumors is currently missing.